Severity of psychiatric and physical problems is associated with lower quality of life in methadone patients in Indonesia

American Journal on Addictions

Volumn 22, Issue 5, 2013, Pages 425-431

  Iskandar, Shelly ^a   Van Crevel, Reinout ^b   Hidayat, Teddy ^a   Siregar, Ike M P ^a   Achmad, Tri H ^a   Van Der Ven, Andre J ^b   De Jong, Cor A ^c  

^a PADJADJARAN UNIVERSITY   (Indonesia)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Nijmegen Institute for Scientist Practitioners in Addiction NISPA   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALANINE AMINOTRANSFERASE; ALCOHOL; AMPHETAMINE; ASPARTATE AMINOTRANSFERASE; BENZODIAZEPINE; BENZODIAZEPINE DERIVATIVE; CANNABIS; COCAINE; CREATININE; DIAMORPHINE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HEMOGLOBIN; LACTATE DEHYDROGENASE; METHADONE; METHAMPHETAMINE; OPIATE;

ABNORMAL LABORATORY RESULT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL ABUSE; ANEMIA; ANXIETY DISORDER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANNABIS ADDICTION; CD4 LYMPHOCYTE COUNT; COCAINE DEPENDENCE; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ABUSE; HEMATOCRIT; HEPATITIS B; HEPATITIS C; HEROIN DEPENDENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDONESIA; LABORATORY TEST; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; MEDICAL RECORD; MENTAL DISEASE; METHADONE TREATMENT; MOOD DISORDER; OPIATE ADDICTION; PHYSICAL DISEASE; PREVALENCE; PSYCHOSIS; QUALITY OF LIFE; QUESTIONNAIRE; SEXUALLY TRANSMITTED DISEASE; SUBSTANCE ABUSE; THROMBOCYTE COUNT; TUBERCULOSIS;

ANXIETY DISORDERS; HEPATITIS C; HEROIN DEPENDENCE; HUMANS; INDONESIA; INTERVIEWS AS TOPIC; MENTAL DISORDERS; OPIATE SUBSTITUTION TREATMENT; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SUBSTANCE-RELATED DISORDERS;

EID: 84882636746     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1111/j.1521-0391.2013.00334.x     Document Type: Article

References (58)

1. Mathers BM, Degenhardt L, Ali H, et al. HIV prevention, treatment, and care services for people who inject drugs: A systematic review of global, regional, and national coverage. Lancet. 2010; 375: 1014-1028.
2. UNAIDS. Epidemiological Fact Sheets on HIV and AIDS, Epidemiological Core Data on Epidemiology and Response, Indonesia, Update 2008. Geneva: WHO; 2008.
3. Connock M, Juarez-Garcia A, Jowett S, et al. Methadone and buprenorphine for the management of opioid dependence: A systematic review and economic evaluation. Health Technol Assess. 2007; 11: 1-171, iii-iv.
4. Mattick RP, Kimber J, Breen C, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2003; CD002207 Review.
5. Mathers BM, Degenhardt L, Phillips B, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: A systematic review. Lancet. 2008; 372: 1733-1745.
6. Berkman ND, Wechsberg WM., Access to treatment-related and support services in methadone treatment programs. J Subst Abuse Treat. 2007; 32: 97-104.
7. Padaiga Z, Subata E, Vanagas G., Outpatient methadone maintenance treatment program. Quality of life and health of opioid-dependent persons in Lithuania. Medicina (Kaunas). 2007; 43: 235-241.
8. Xiao L, Wu Z, Luo W, et al. Quality of life of outpatients in methadone maintenance treatment clinics. J Acquir Immune Defic Syndr. 2010; 53 (Suppl. 1): S116-S120.
9. Lawrinson P, Ali R, Buavirat A, et al. Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS. Addiction. 2008; 103: 1484-1492.
10. Degenhardt L, Mathers B, Vickerman P, et al. Prevention of HIV infection for people who inject drugs: Why individual, structural, and combination approaches are needed. Lancet. 2010; 376: 285-301.
11. Bergenstrom AM, Abdul-Quader AS., Injection drug use, HIV and the current response in selected low-income and middle-income countries. AIDS. 2010; 24 (Suppl. 3): S20-S29.
12. McCarthy JJ, Flynn N., Hepatitis C in methadone maintenance patients: Prevalence and public policy implications. J Addict Dis. 2001; 20: 19-31.
13. Cacciola JS, Alterman AI, Rutherford MJ, et al. The relationship of psychiatric comorbidity to treatment outcomes in methadone maintained patients. Drug Alcohol Depend. 2001; 61: 271-280.
14. Carpentier PJ, Krabbe PF, van Gogh MT, et al. Psychiatric comorbidity reduces quality of life in chronic methadone maintained patients. Am J Addict. 2009; 18: 470-480.
15. Stenbacka M, Beck O, Leifman A, et al. Problem drinking in relation to treatment outcome among opiate addicts in methadone maintenance treatment. Drug Alcohol Rev. 2007; 26: 55-63.
16. Brands B, Blake J, Marsh DC, et al. The impact of benzodiazepine use on methadone maintenance treatment outcomes. J Addict Dis. 2008; 27: 37-48.
17. Peles E, Schreiber S, Adelson M., Tricyclic antidepressants abuse, with or without benzodiazepines abuse, in former heroin addicts currently in methadone maintenance treatment (MMT). Eur Neuropsychopharmacol. 2008; 18: 188-193.
18. Altice FL, Kamarulzaman A, Soriano VV, et al. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet. 2010; 376: 367-387.
19. Munoz-Moreno JA, Fumaz CR, Ferrer MJ, et al. Neuropsychiatric symptoms associated with efavirenz: Prevalence, correlates, and management. A neurobehavioral review. AIDS Rev. 2009; 11: 103-109.
20. Gruber VA, McCance-Katz EF., Methadone, buprenorphine, and street drug interactions with antiretroviral medications. Curr HIV/AIDS Rep. 2010; 7: 152-160.
21. Pisani E, Dadun, Sucahya PK, et al. Sexual behavior among injection drug users in 3 Indonesian cities carries a high potential for HIV spread to noninjectors. J Acquir Immune Defic Syndr. 2003; 34: 403-406.
22. Mesquita F, Winarso I, Atmosukarto II, et al. Public health the leading force of the Indonesian response to the HIV/AIDS crisis among people who inject drugs. Harm Reduct J. 2007; 4: 9.
23. Willenbring ML., Integrating care for patients with infectious, psychiatric, and substance use disorders: Concepts and approaches. AIDS. 2005; 19 (Suppl. 3): S227-S237.
24. Vanagas G, Padaiga Z, Subata E., Drug addiction maintenance treatment and quality of life measurements. Medicina (Kaunas). 2004; 40: 833-841.
25. Yen CN, Wang CS, Wang TY, et al. Quality of life and its correlates among heroin users in Taiwan. Kaohsiung J Med Sci. 2011; 27: 177-183.
26. Heckathorn DD, Semaan S, Broadhead RS, et al. Extensions of respondent-driven sampling: A new approach to the study of injection drug users aged 18-25. AIDS Behav. 2002; 6: 55-67.
27. Iskandar S, Basar D, Hidayat T, et al. High risk behavior for HIV transmission among former injecting drug users: A survey from Indonesia. BMC Public Health. 2010; 10: 472.
28. Alisjahbana B, Susanto H, Roesli R, et al. Prevention, control, and treatment of HIV-AIDS among injecting drug user in Bandung, Indonesia. Acta Med Indones. 2009; 41 (Suppl. 1): 65-69.
29. McLellan AT, Cacciola JS, Alterman AI, et al. The Addiction Severity Index at 25: Origins, contributions and transitions. Am J Addict. 2006; 15: 113-124.
30. WHO. WHO Collaborative Study on Substitution Therapy of Opioid Dependence and HIV/AIDS: General Protocol. 2003; http://www.who.int/substance-abuse/ research-tools/translation/en/print.html. Accessed May 1, 2008.
31. Addiction Severity Index: Manual and Question by Question Guide. 1990; Treatment Research Institute (TRI). Available at: http://www.tresearch.org/ resources/manuals/ASIQbyQGuide.pdf. Accessed May 1, 2008.
32. van den Brink W, Hendriks VM, Blanken P, et al. Medical prescription of heroin to treatment resistant heroin addicts: Two randomised controlled trials. BMJ. 2003; 327: 310-312.
33. McGahan PL, Griffith JA, Parente R, et al. Addiction Severity Index: Composite Scores Manual; 1986. http://www.tresearch.org/resources/compscores/ CompositeManual.pdf.
34. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998; 59 (Suppl. 20): 22-33, quiz 34-57.
35. Bhui K, Craig T, Mohamud S, et al. Mental disorders among Somali refugees: Developing culturally appropriate measures and assessing socio-cultural risk factors. Soc Psychiatry Psychiatr Epidemiol. 2006; 41: 400-408.
36. Centre for Health Economics, University of York, United Kingdom. EuroQol-A new facility for the measurement of health-related quality of life. Health Policy. 1990; 16: 199-208.
37. Dolan P., Modeling valuations for EuroQol health states. Med Care. 1997; 35: 1095-1108.
38. Langenhoff BS, Krabbe PF, Peerenboom L, et al. Quality of life after surgical treatment of colorectal liver metastases. Br J Surg. 2006; 93: 1007-1014.
39. Schafer A, Wittchen HU, Backmund M, et al. Psychopathological changes and quality of life in hepatitis C virus-infected, opioid-dependent patients during maintenance therapy. Addiction. 2009; 104: 630-640.
40. Thumboo J, Fong KY, Machin D, et al. Quality of life in an urban Asian population: The impact of ethnicity and socio-economic status. Soc Sci Med. 2003; 56: 1761-1772.
41. Kresina TF, Normand J, Khalsa J, et al. Addressing the need for treatment paradigms for drug-abusing patients with multiple morbidities. Clin Infect Dis. 2004; 38 (Suppl. 5): S398-S401.
42. Sylvestre DL, Loftis JM, Hauser P, et al. Co-occurring hepatitis C, substance use, and psychiatric illness: Treatment issues and developing integrated models of care. J Urban Health. 2004; 81: 719-734.
43. Friedland G., Infectious disease comorbidities adversely affecting substance users with HIV: Hepatitis C and tuberculosis. J Acquir Immune Defic Syndr. 55 (Suppl. 1): S37-S42.
44. Gelkopf M, Weizman T, Melamed Y, et al. Does psychiatric comorbidity affect drug abuse treatment outcome? A prospective assessment of drug abuse, treatment tenure and infectious diseases in an Israeli methadone maintenance clinic. Isr J Psychiatry Relat Sci. 2006; 43: 126-136.
45. Devi KhS, Singh NB, Singh HL, et al. Coinfection by human immunodeficiency virus, hepatitis B virus and hepatitis C virus in injecting drug users. J Indian Med Assoc. 2009; 107: 144, 146-147.
46. Ngowi BJ, Mfinanga SG, Bruun JN, et al. Pulmonary tuberculosis among people living with HIV/AIDS attending care and treatment in rural northern Tanzania. BMC Public Health. 2008; 8: 341.
47. Chiang SC, Chan HY, Chang YY, et al. Psychiatric comorbidity and gender difference among treatment-seeking heroin abusers in Taiwan. Psychiatry Clin Neurosci. 2007; 61: 105-111.
48. Trafton JA, Minkel J, Humphreys K., Opioid substitution treatment reduces substance use equivalently in patients with and without posttraumatic stress disorder. J Stud Alcohol. 2006; 67: 228-235.
49. Peles E, Schreiber S, Naumovsky Y, et al. Depression in methadone maintenance treatment patients: Rate and risk factors. J Affect Disord. 2007; 99: 213-220.
50. Tegger MK, Crane HM, Tapia KA, et al. The effect of mental illness, substance use, and treatment for depression on the initiation of highly active antiretroviral therapy among HIV-infected individuals. AIDS Patient Care STDS. 2008; 22: 233-243.
51. Gourevitch MN, Chatterji P, Deb N, et al. On-site medical care in methadone maintenance: Associations with health care use and expenditures. J Subst Abuse Treat. 2007; 32: 143-151.
52. Wobrock T, Sittinger H, Behrendt B, et al. Comorbid substance abuse and neurocognitive function in recent-onset schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2007; 257: 203-210.
53. Thirthalli J, Chand PK., The implications of medication development in the treatment of substance use disorders in developing countries. Curr Opin Psychiatry. 2009; 22: 274-280.
54. Afriandi I, Siregar AY, Meheus F, et al. Costs of hospital-based methadone maintenance treatment in HIV/AIDS control among injecting drug users in Indonesia. Health Policy. 95: 69-73.
55. Siregar AY, Komarudin D, Leuwol B, et al. Economic aspect of HIV/AIDS control and injecting drug use in Indonesia. Acta Med Indones. 2009; 41 (Suppl. 1): 70-74.
56. Salganik MJ, Heckathorn DD., Sampling and estimation in hidden populations using respondent driven sampling. Sociol Method. 2004; 34: 193-240.
57. Platt L, Wall M, Rhodes T, et al. Methods to recruit hard-to-reach groups: Comparing two chain referral sampling methods of recruiting injecting drug users across nine studies in Russia and Estonia. J Urban Health. 2006; 83 (Suppl. 6): i39-i53.
58. Trotter RT II, Bowen AM, Potter JM Jr., Network models for HIV outreach and prevention programs for drug users. NIDA Res Monogr. 1995; 151: 144-180.